Measuring Solid Tumors Using Response Evaluation Criteria in Solid Tumors (RECIST)

SOP #: PM-5

Next Review Date: 06/2013

Version #: 1.3

Review Interval Period: Biennial

Approved Version #: 1.3 Date: 06/2011

Policy Reference:

Purpose: To identify the process to be followed when using RECIST criteria to evaluate solid tumors.
STEP 1: Confirm RECIST Criteria Are Used in the Protocol to Determine Solid Tumor Response
  1. If RECIST criteria has been selected as the method to evaluate solid tumors response, it should be specified in the protocol including the RECIST version (i.e., 1.0 or 1.1) and the evaluation timeline.
  2. If RECIST is not used to determine solid tumor response, the protocol should detail how tumor response will be evaluated including response definitions.
STEP 2: Using RECIST When Documenting Measurements of Target and Non-Target Lesions
  1. A consistent physician-of-record or designee should identify and measure target lesions and non-target lesions at baseline and at the protocol-specific evaluation timeline.
  2. All target and non-target lesions should be documented in CRIS on the Tumor Measurement/RECIST flow sheet at the time of initial measurement.
  3. If protocol uses C3D, abstract/record tumor measurement data from CRIS documentation.